Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Income (2020 - 2025)

Historic Operating Income for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$28.3 million.

  • Pliant Therapeutics' Operating Income rose 5441.51% to -$28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.1 million, marking a year-over-year increase of 1619.49%. This contributed to the annual value of -$228.4 million for FY2024, which is 2401.37% down from last year.
  • As of Q3 2025, Pliant Therapeutics' Operating Income stood at -$28.3 million, which was up 5441.51% from -$45.6 million recorded in Q2 2025.
  • Pliant Therapeutics' Operating Income's 5-year high stood at -$22.9 million during Q2 2021, with a 5-year trough of -$62.0 million in Q3 2024.
  • Over the past 5 years, Pliant Therapeutics' median Operating Income value was -$42.1 million (recorded in 2023), while the average stood at -$40.5 million.
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 30820.31% in 2021, then surged by 5441.51% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Operating Income stood at -$24.6 million in 2021, then crashed by 52.04% to -$37.4 million in 2022, then dropped by 25.77% to -$47.0 million in 2023, then decreased by 13.36% to -$53.3 million in 2024, then soared by 46.98% to -$28.3 million in 2025.
  • Its Operating Income was -$28.3 million in Q3 2025, compared to -$45.6 million in Q2 2025 and -$58.9 million in Q1 2025.